Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer

References

• Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52–62
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784–96
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486–92
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559–70
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53
   PubMed Web of Science ®Google Scholar
• Brodie AH, Jelovac D, Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Biol 2003;86:283–8
   PubMed Web of Science ®Google Scholar
• Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13:829–37
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 2014;17:252–9
   PubMed Web of Science ®Google Scholar
• Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 2008;15:73–90
   PubMed Web of Science ®Google Scholar
• Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011;22:857–62
   PubMed Web of Science ®Google Scholar
• Rabaglio M, Sun Z, Price KN, et al. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;20:1489–98
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709–22
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Knoll D, Struck M, Hars O, Bauer T, Hadji P. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. J Cancer Res Clin Oncol 2014;140:159–66
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218–26
   PubMed Web of Science ®Google Scholar
• Hadji P, Kauka A, Bauer T, Tams J, Hasenburg A, Kieback DG. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric 2012;15: 460–6
   PubMed Web of Science ®Google Scholar
• Johansson H, Bonanni B, Gandini S, et al. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. Breast Cancer Res Treat 2013;142:569–78
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Rachner TD, Urbschat A, Hars O, Hofbauer LC, Hadji P. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol 2014 June 7. Epub ahead of print
   Web of Science ®Google Scholar
• Mitwally MF, Casper RF, Diamond MP. Oestrogen-selective modulation of FSH and LH secretion by pituitary gland. Br J Cancer 2005;92:416–17
   PubMed Web of Science ®Google Scholar
• van Londen GJ, Perera S, Vujevich K, et al. The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. Breast Cancer Res Treat 2011;125:441–6
   PubMed Web of Science ®Google Scholar
• Evans TR, Di Salle E, Ornati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933–9
   PubMed Web of Science ®Google Scholar
• Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101–8
   PubMed Web of Science ®Google Scholar
• Rossi E, Morabito A, Di Rella F, et al. Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009;27:3192–7
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2
   PubMed Web of Science ®Google Scholar
• Naessen T1, Sjogren U, Bergquist J, Larsson M, Lind L, Kushnir MM. Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women. J Clin Endocrinol Metab 2010;95:1889–97
   PubMed Web of Science ®Google Scholar